Lannett gets FDA nod for generic butalbital, acetaminophen and caffeine capsulesThe two dosage strengths of BAC capsules have a combined estimated market value of approximately $68.6 million for the 12 months ended October 2019. Allergan gets FDA OK for UbrelvyUbrelvy is the first and only oral calcitonin gene-related peptide receptor antagonist for the treatment of migraine attacks once they start. Dr. Reddy's intros generic Nitropress The Nitropress brand and generics had a market value of approximately $8 million for the most recent 12 months ended October 2019. FDA approves expanded indication for Amarin’s Vascepa Vascepa was originally approved as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. Ortho Dermatologics gets FDA green light for Arazlo Arazlo is the first FDA approved tazarotene acne treatment in a lotion formulation. Focus On: Pharma Logistics’ speed keeps it and its customers thriving Michael Zaccaro, president and CEO of Pharma Logistics, discusses its Rapid Credit Program, which puts the onus on Pharma Logistics, not the pharmacy. Amneal names 3 executives to its board of directors Jeff George, John Kiely and Shlomo Yanai have been appointed to Amneal’s board of directors. Lupin gets FDA OK for generic Myfortic, launches generic Hectorol Mycophenolic acid delayed-release tablets and doxercalciferol injection had a market value of roughly $174 million and $132 million, respectively. E5 Pharma launches generic Proglycem e5 Pharma's diazoxide oral suspension is the first generic of Proglycem. Merck gets FDA green light for Ervebo Merck's Ervebo is indicated for the prevention of disease caused by Zaire ebolavirus in individuals 18 years old and older. First Previous 421 422 423 424 425 Next Last
